Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Glioma · Malignant Brain Neoplasm · Meningioma · Metastatic Malignant Neoplasm in the Brain

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Contact: Study coordinator (Sichen Li) · sichenli@mednet.ucla.edu · 310-794-5663
Contact: Principal Investigator (Robert M. Prins, PhD)

Study leads

Robert M Prins
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Glioblastoma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma

Abroad (travel likely)RecruitingPHASE2

New York, United States

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Astrocytoma · Glioma · Recurrent Glioblastoma

Abroad (travel likely)RecruitingPHASE1

Bethesda, United States

F-Tryptophan PET/CT in Human Cancers

Intracranial Glioma · Metastatic Brain Tumor · Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Detroit, United States

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Gliomas Harboring IDH1 and/or IDH2 Mutations

Abroad (travel likely)RecruitingPHASE1

Shanghai, China